Treatment of Alzheimer disease.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  American Family Physician

• Publication date

  2011-06-15

• Fields of study

  Medicine

• Identifiers
  PMID 21671540
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

  2017cited by this paper
• Vitamin E for Alzheimer's dementia and mild cognitive impairment.

  2012cited by this paper
• The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Lack of evidence for the efficacy of memantine in mild Alzheimer disease.

  2011cited by this paper
• The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011cited by this paper
• Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis

  2010cited by this paper
• Current treatment and recent clinical research in Alzheimer's disease.

  2010cited by this paper
• Alzheimer's disease.

  2010cited by this paper
• NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.

  2010cited by this paper
• Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease

  2010cited by this paper
• Adverse events associated with testosterone administration.

  2010cited by this paper
• Safety and Tolerability of Donepezil, Rivastigmine and Galantamine for Patients with Alzheimer’s Disease: Systematic Review of the ‘Real-World’ Evidence

  2009cited by this paper
• A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease

  2009cited by this paper
• Ginkgo biloba extract EGb 761®, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial

  2009cited by this paper
• Hormone replacement therapy to maintain cognitive function in women with dementia.

  2009cited by this paper
• Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

  2008influential reference
• Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease

  2008cited by this paper
• Vitamin E for Alzheimer's disease and mild cognitive impairment.

  2008cited by this paper
• Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

  2008cited by this paper
• Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.

  2008cited by this paper
• Physical activity and the maintenance of cognitive function

  2007cited by this paper
• American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition.

  2007cited by this paper
• Introduction: The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006

  2007cited by this paper
• IANA task force on nutrition and cognitive decline with aging.

  2007cited by this paper
• Antipsychotic Drug Use and Mortality in Older Adults with Dementia

  2007cited by this paper
• Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

  2007cited by this paper
• Ginkgo biloba for cognitive impairment and dementia.

  2007cited by this paper
• Antihypertensive medication use and incident Alzheimer disease: the Cache County Study.

  2006cited by this paper
• Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men.

  2006cited by this paper
• Atypical antipsychotics for aggression and psychosis in Alzheimer's disease

  2006cited by this paper
• Cognitive Reserve and Alzheimer Disease

  2006cited by this paper
• Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

  2005cited by this paper
• Memantine for dementia.

  2005cited by this paper
• Guidelines for the Treatment of Alzheimer’s Disease from the Italian Association of Psychogeriatrics

  2005cited by this paper
• Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment

  2005cited by this paper
• Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

  2004cited by this paper
• Rofecoxib

  2004cited by this paper
• Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.

  2003cited by this paper
• Selegiline for Alzheimer's disease.

  2003cited by this paper
• Ibuprofen for Alzheimer's disease.

  2003cited by this paper
• No additional benefit of HRT on response to rivastigmine in menopausal women with AD

  2003cited by this paper
• Acetyl-L-carnitine for dementia.

  2003cited by this paper
• A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease

  2003cited by this paper
• The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.

  2002cited by this paper
• Indomethacin for Alzheimer's disease

  2002cited by this paper
• Hormone replacement therapy to maintain cognitive function in women with dementia.

  2002cited by this paper
• Indomethacin for the treatment of Alzheimer's disease patients.

  2002cited by this paper
• Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics

  2001cited by this paper
• Lecithin for dementia and cognitive impairment.

  2000cited by this paper
• Cholinesterase Inhibitors in Alzheimer's Disease

  1994influential reference
• The Clinical Dementia Rating (CDR)

  1993cited by this paper

• Pistagremic acid from Pistacia integerrima as a natural multi-target candidate tackling crucial enzymes involved in Alzheimer’s disease

  2026cites this paper
• ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer's disease.

  2026cites this paper
• FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?

  2026cites this paper
• Cross-Validation of Neurodegeneration Biomarkers in Blood and CSF for Dementia Classification

  2026cites this paper
• Unveiling the Therapeutic Potential of Piper chaba Hunter: Computational Approaches Shed Light on Targeting Proteins in Alzheimer's Disease

  2025cites this paper
• Characterizing the Journey of Early Alzheimer’s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study

  2025cites this paper
• Targeting Microglial Activation to Modulate Neuroinflammation in Alzheimer’s Disease

  2025cites this paper
• A review on recent advances in Alzheimer's disease: The role of synaptic plasticity

  2025influential citation
• Development of donepezil hydrochloride-loaded PLGA-based nanoparticles for Alzheimer’s disease treatment

  2025cites this paper
• Alzheimer’s Disease Drug Design by Synthesis, Characterization, Enzyme Inhibition, In Silico, SAR Analysis and MM-GBSA Analysis of Schiff Bases Derivatives

  2025cites this paper
• Unraveling the Therapeutic Potential of Alzheimer’s Drugs: A Comprehensive Review

  2025cites this paper
• Utilizing Sequential Information of General Lab-test Results and Diagnoses History for Differential Diagnosis of Dementia

  2025cites this paper
• Medication prescriptions among patients with mild cognitive impairment and Alzheimer's disease: A large nationwide electronic health record cohort study

  2025cites this paper
• Neuroprotective Potential of Phytocompounds in the Treatment of Dementia: The State of Knowledge from the Scopolamine-Induced Animal Model of Alzheimer’s Disease

  2025cites this paper
• Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort

  2025cites this paper
• Lecanemab-irmb (Leqembi™) for Treatment of Alzheimer's Disease.

  2024cites this paper
• Neuropsychiatric Symptoms in Dementia

  2024cites this paper
• Vascular Cognitive Impairment

  2024cites this paper
• Neuroimaging in Dementia

  2024cites this paper
• Diagnosing Alzheimer Disease

  2024cites this paper
• Genetics and Neuropathology of Neurodegenerative Dementias

  2024cites this paper
• Demographics, comorbidities, and comedications in newly diagnosed patients with Alzheimer's disease and related dementias: Findings from United States Medicare claims data

  2024influential citation
• Developing a Treatment Method for Dementia and Delirium Patients using Virtual Reality

  2024cites this paper
• Chamuangone-rich rice bran oil ameliorates neurodegeneration in AlCl3/D-galactose model viamodulation of behavioral, biochemical, and neurochemical parameters

  2024cites this paper
• Cross-Sectional and Longitudinal Associations Between Treatment for Herpes Virus Infection and the Dispensing of Antidementia Medicines: An Analysis of the Australian Pharmaceutical Benefits Scheme Database

  2024cites this paper
• Familial Alzheimer’s Disease Neurons Bearing Mutations in PSEN1 Display Increased Calcium Responses to AMPA as an Early Calcium Dysregulation Phenotype

  2024cites this paper
• Some promising medicinal plants used in Alzheimer’s disease: an ethnopharmacological perspective

  2024cites this paper
• Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia

  2024cites this paper
• Differential Effects of Endocannabinoids on Amyloid-Beta Aggregation and Toxicity

  2023cites this paper
• Integrated approach to reducing polypharmacy in older people: exploring the role of oxidative stress and antioxidant potential therapy

  2023cites this paper
• Neurodiagnostic and neurotherapeutic potential of graphene nanomaterials.

  2023cites this paper
• Pentoxifylline as Add-On Treatment to Donepezil in Copper Sulphate-Induced Alzheimer’s Disease-Like Neurodegeneration in Rats

  2023cites this paper
• Antidotes in Clinical Toxicology—Critical Review

  2023cites this paper
• Age-related pathophysiological alterations in molecular stress markers and key modulators of hypoxia.

  2023cites this paper
• N,N-dimethylacetamide targets neuroinflammation in Alzheimer’s disease in in-vitro and ex-vivo models

  2023cites this paper
• Molecular Targets Underlying the Neuroprotective Effects of Boswellic acid: A Systematic Review.

  2023cites this paper
• The effectiveness and safety of Jihwang-eumja (Dihuang Yizi) compared to Western medications in patients with Alzheimer's disease: A systematic review and meta-analysis.

  2023cites this paper
• How Can Insulin Resistance Cause Alzheimer’s Disease?

  2023cites this paper
• Protective Effects of Polysaccharides in Neurodegenerative Diseases

  2022cites this paper
• The Potential Therapeutic Effects of Low-Dose Ionizing Radiation in Alzheimer's Disease

  2022cites this paper
• Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial

  2022cites this paper
• Real-World Use of Symptomatic Treatments in Early Alzheimer’s Disease

  2022cites this paper
• Glial Cell-Mediated Neuroinflammation in Alzheimer’s Disease

  2022cites this paper
• Assessment of the neuroprotective potential of d-cycloserine and l-serine in aluminum chloride-induced experimental models of Alzheimer’s disease: In vivo and in vitro studies

  2022cites this paper
• Revealing the Acetylcholinesterase Inhibitory Potential of Phyllanthus amarus and Its Phytoconstituents: In Vitro and in Silico Approach

  2022cites this paper
• A Preliminary Assessment of the Nutraceutical Potential of Acai Berry (Euterpe sp.) as a Potential Natural Treatment for Alzheimer’s Disease

  2022influential citation
• Association of serum s-adenosylmethionine, s-adenosylhomocysteine, and their ratio with the risk of dementia and death in a community

  2022cites this paper
• Melissa officinalis (lemon balm)

  2021cites this paper
• Alzheimer’s disease therapy and effects of genetic polymorphisms on its efficacy and safety

  2021cites this paper
• Disability and the Goods of Life.

  2021cites this paper
• The effect of a multimodal dementia prevention program involving community‐dwelling elderly

  2021cites this paper
• A Brief Review of Alzheimer’s Disease

  2021cites this paper
• Running to save sight: The effects of exercise on retinal health and function

  2021cites this paper
• Erinacine A-Enriched Hericium erinaceus Mycelium Delays Progression of Age-Related Cognitive Decline in Senescence Accelerated Mouse Prone 8 (SAMP8) Mice

  2021cites this paper
• Gender Disparities in Anti-dementia Medication Use among Older Adults: Health Equity Considerations and Management of Alzheimer's Disease and Related Dementias

  2021cites this paper
• Chemical update on the potential for serotonin 5-HT6 and 5-HT7 receptor agents in the treatment of Alzheimer's disease.

  2021cites this paper
• Prevalence of and risk factors for adverse events in Alzheimer’s patients receiving anti-dementia drugs in at-home care

  2020cites this paper
• Dementia and usage of N-methyl-d-aspartate receptor antagonists

  2020cites this paper
• Alzheimer and It’s Possible Therapy: A Review

  2020cites this paper
• Pathophysiology

  2020cites this paper
• Health Outcomes Research of Novel Disease Modifying Medications in Alzheimerâ•Žs Disease and Cost Burden of Early Onset Dementia

  2020influential citation
• Pharmaceutical Treatment for Alzheimer’s Disease and Related Dementias: Utilization and Disparities

  2020cites this paper
• Umbrella branding in pharmaceutical markets.

  2020influential citation
• Synthesis of Novel 2,3-Dihydro-5,6-dimethoxy-2-((piperidin-4-yl)methyl) inden-1-one Derivatives as Acetyl Cholinesterase Inhibitors

  2020cites this paper
• Progress in Target Drug Molecules for Alzheimer's Disease.

  2019cites this paper
• Traditional Ayurvedic and herbal remedies for Alzheimer’s disease: from bench to bedside

  2019cites this paper
• Ethanol Extract of Centipeda minima Exerts Antioxidant and Neuroprotective Effects via Activation of the Nrf2 Signaling Pathway

  2019cites this paper
• High-throughput metabolomics and ingenuity pathway approach reveals the pharmacological effect and targets of Ginsenoside Rg1 in Alzheimer’s disease mice

  2019cites this paper
• Longitudinal analysis of dementia diagnosis and specialty care among racially diverse Medicare beneficiaries

  2019cites this paper
• Trends in the Use of Medications and Supplements to Treat or Prevent Dementia

  2019cites this paper
• Okra polysaccharides can reverse the metabolic disorder induced by high-fat diet and cognitive function injury in Aβ1-42 mice.

  2019cites this paper
• Pharmacists a valuable resource for patients with Alzheimer disease and their caregivers

  2019cites this paper
• Alzheimer’s Disease and Parkinson’s Disease: A Nutritional Toxicology Perspective of the Impact of Oxidative Stress, Mitochondrial Dysfunction, Nutrigenomics and Environmental Chemicals

  2019cites this paper
• A summary of the evidence and evaluation of the effectiveness of nonpharmacological interventions for mild cognitive impairment

  2019cites this paper
• Investigating the biochemical signature and in vivo seeding activity of amyloid-β from distinct Alzheimer's Disease subtypes

  2019cites this paper
• Organoruthenium Prodrugs as a New Class of Cholinesterase and Glutathione‐S‐Transferase Inhibitors

  2018cites this paper
• Is testosterone perspective available for neurodegenerative diseases

  2018cites this paper
• Anesthesia in patients with neurological diseases: Coma (neurological disorders and anesthesia)

  2018cites this paper
• Review of Alzheimer’s Disease Treatment and Potential Future Therapies

  2018cites this paper
• Assessing implicit and explicit dementia stigma in young adults and care-workers

  2018cites this paper
• Therapy of Dredging the Bowels Enhanced the Neuroprotective Effect of Nourishing Kidney Herbs on Hippocampal Cholinergic System in Alzheimer's Disease Model Rat Induced by Aβ 1-42

  2018cites this paper
• Alzheimer’s Disease – The Past, the Present and the Future

  2017cites this paper
• Newly Developed Drugs for Alzheimer's Disease in Relation to Energy Metabolism, Cholinergic and Monoaminergic Neurotransmission.

  2017cites this paper
• GENETIC DISORDER ALZHEIMER

  2017cites this paper
• A Systematic Review of Practice Guidelines and Recommendations for Discontinuation of Cholinesterase Inhibitors in Dementia.

  2017cites this paper
• Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer’s disease

  2017cites this paper
• Non-Pharmacologic Interventions for Older Adults with Subjective Cognitive Decline: Systematic Review, Meta-Analysis, and Preliminary Recommendations

  2017cites this paper
• Polysaccharides from Ganoderma lucidum Promote Cognitive Function and Neural Progenitor Proliferation in Mouse Model of Alzheimer's Disease

  2017cites this paper
• Genome instability in Alzheimer disease.

  2017cites this paper
• Update on Dementia. Pathophysiology, Diagnosis, and Treatment. DSM-IV versus DSM-V

  2017cites this paper
• Effect of cold compressed coconut oil on cognition and behavior among patients with Alzheimer's disease - A pilot intervention study

  2017cites this paper
• Hypoxia‐inducible factors as neuroprotective agent in Alzheimer's disease

  2017cites this paper
• Candidate SNP Markers of Familial and Sporadic Alzheimer's Diseases Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene Promoters

  2017cites this paper
• Cholinergic symptoms and QTc prolongation following donepezil overdose.

  2017cites this paper
• Tilburg University Umbrella Branding in Pharmaceutical Markets

  2017cites this paper
• Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms.

  2017cites this paper
• Effect of the herbal formulation Shen-Zhi-Ling on an APP/PS1 mouse model of Alzheimer's disease by modulating the biliverdin reductase/heme oxygenase 1 system

  2017cites this paper
• Health Outcomes Research of Novel Disease Modifying Medications in Alzheimer’s Disease and Cost Burden of Early Onset Dementia

  2017influential citation
• BACE Inhibitors and Tau Protein Targeting Drugs in Prevention of Alzheimer’s Disease

  2017cites this paper
• Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies

  2017cites this paper